ACTREC et al., 2026-09-25: Head and neck (other): the only randomized trial of ivermectin as an anticancer agent registered anywhere in this sweep, 130 patients, not yet recruiting.
A Phase II Randomized Trial of Ivermectin plus Chemo-Immunotherapy versus Chemo-Immunotherapy alone
ACTREC et al., 2026-09-25: Head and neck (other): the only randomized trial of ivermectin as an anticancer agent registered anywhere in this sweep, 130 patients, not yet recruiting. C7 – cancer type: head and neck squamous cell carcinoma (listed under 'other'). Registered, no results. This is the strongest test of the anticancer hypothesis now in the field: randomized, active-controlled, PFS primary endpoint. Dose: ivermectin 12 mg PO twice weekly (a low, anti-parasitic-range dose compared with the 1-2 mg/kg/day used in case reports). Funding ACTREC/TMC. Registry entry; no results posted. Also filed as IVD-03 (claims C1, C7). Study type: regulatory record.
